Pharvaris Announces Annual General Meeting of Shareholders
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pharvaris (Nasdaq: PHVS) announced its annual general meeting of shareholders will be held on Friday, June 26, 2026, at 16:00 CEST (10:00 a.m. EDT).
Meeting documents, including the notice and agenda, are available in the website’s Investors > Events & Presentations section and on the SEC website.
Details
News Market Reaction – PHVS
On Jun 11, the day this news came out, PHVS closed 2.19% above the previous close.
Data tracked by StockTitan Argus for the Jun 11 session.
Key Figures
- AGM date
- June 26, 2026
- Scheduled date of annual general meeting
- AGM time CEST
- 16:00 CEST
- Local time of annual general meeting
- AGM time EDT
- 10:00 a.m. EDT
- US Eastern time of annual general meeting
Historical Context
-
Announcement of multiple Phase 2/3 deucrictibant data presentations at EAACI 2026.
-
Q1 2026 update with €247M cash, added $132.3M raise, and clear HAE timelines.
-
Closing of $132.3M underwritten offering of 4,455,863 ordinary shares.
-
Pricing of $115M share offering at $29.68 per share with 30-day option.
-
Conference data on combined deucrictibant IR/XR use showing supportive safety margins.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
bradykinin b2 receptor antagonists medical
hereditary angioedema medical
acquired angioedema medical
c1 inhibitor deficiency medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the annual general meeting of shareholders will take place on Friday, June 26, 2026, at 16:00 CEST (10:00 a.m. EDT).
All relevant documents and information relating to the annual general meeting, including the notice and agenda for the annual general meeting, are or will be made available in the “Investors” section of Pharvaris’ website under “Events & Presentations”. The documents will also be made available on the SEC’s website at www.sec.gov. Shareholders who wish to attend the meeting should register as described in the notice and agenda for the annual general meeting.
About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. Pharvaris is preparing marketing authorization applications for deucrictibant immediate-release capsule as an on-demand treatment of HAE attacks, and a global pivotal Phase 3 study of deucrictibant extended-release tablet for the prevention of HAE attacks (CHAPTER-3) is ongoing with topline data anticipated in the third quarter of 2026. In addition, CREAATE is an ongoing Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks. For more information, visit https://pharvaris.com/.

Contact Maggie Beller Vice President, Head of Corporate and Investor Communications maggie.beller@pharvaris.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.